Tirzepatide

Key Research Papers and Clinical Trials

Recent research on tirzepatide spans several important areas, including safety monitoring, cardiovascular outcomes, and effects on eating behaviors.

Safety and Adverse Events

A 2024 pharmacovigilance study analyzed real-world safety data from the FDA Adverse Event Reporting System (FAERS) database to examine tirzepatide's safety profile in clinical practice. Additionally, a case report documented acute small bowel obstruction potentially induced by tirzepatide, highlighting the importance of monitoring for gastrointestinal complications.

Research has also examined the periprocedural safety of continuing GLP-1 receptor agonists like tirzepatide prior to cardiac catheterization procedures.

Cardiovascular Outcomes

A systematic review and meta-analysis evaluated tirzepatide's effects on cardiovascular outcomes and mortality in patients with obesity and diabetes, though specific sample sizes and detailed findings are not available from the provided evidence.

Behavioral and Dietary Effects

The CRAVE study investigated changes in food cravings, dietary quality, body composition, and dietary intake during GLP-1 receptor agonist therapy. A separate observational study examined changes in taste and eating habits associated with GLP-1 agonists in weight loss patients.

The PERCEPTIONS survey collected data on reasons for initiating tirzepatide and patient experiences among individuals with obesity or overweight.

Ongoing Clinical Research

Several active clinical trials are investigating tirzepatide's applications:

• A Phase 2 study (NCT06603571) is testing tirzepatide alone or in combination with another compound (LY3841136) for weight management in adults with obesity or overweight and type 2 diabetes
• A Phase 4 trial (NCT07326111) is examining tirzepatide's effects on reproductive function and metabolic health in women with PCOS who are overweight or obese
• A completed Phase 3 study (NCT06221969) compared a combination therapy called CagriSema to tirzepatide for blood sugar and weight reduction
• A Phase 4 study (NCT06857942) is investigating tirzepatide's effectiveness following initiation of another medication in patients with psoriasis and obesity

Research Gaps

The evidence shows active investigation into tirzepatide's broader effects beyond diabetes and weight management, including reproductive health and eating behaviors. However, detailed results from many of these studies are not yet available in the provided evidence.

Note: This synthesis is based on limited evidence from study titles and registry information. Detailed study results, sample sizes, and specific findings are not available for most studies mentioned.